Provided by Tiger Fintech (Singapore) Pte. Ltd.

Madrigal Pharmaceuticals

348.35
+25.337.84%
Post-market: 348.350.00000.00%19:49 EDT
Volume:382.11K
Turnover:130.08M
Market Cap:7.69B
PE:-15.91
High:348.35
Open:328.50
Low:326.70
Close:323.02
Loading ...

Madrigal Pharmaceuticals appoints Fouse to its board of directors

TIPRANKS
·
11 Mar

Press Release: Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors

Dow Jones
·
11 Mar

Madrigal Pharmaceuticals Exec Cashes Out in Multi-Million Dollar Stock Sale!

TIPRANKS
·
08 Mar

TD Cowen Sticks to Their Buy Rating for Madrigal Pharmaceuticals (MDGL)

TIPRANKS
·
06 Mar

B. Riley Upgrades Madrigal Pharmaceuticals to Buy From Neutral, Raises Price Target to $422 From $236

MT Newswires Live
·
28 Feb

Madrigal Pharmaceuticals Is Maintained at Buy by Citigroup

Dow Jones
·
28 Feb

Madrigal Pharmaceuticals Shares Still Undervalued Amid Long-Term Growth Potential, UBS Says

MT Newswires Live
·
28 Feb

Analysts Offer Insights on Healthcare Companies: Schrodinger (SDGR), Madrigal Pharmaceuticals (MDGL) and Ligand Pharma (LGND)

TIPRANKS
·
27 Feb

Madrigal Pharmaceuticals price target raised to $239 from $154 at BofA

TIPRANKS
·
27 Feb

Madrigal Pharmaceuticals Inc : B. Riley Raises to Buy From Neutral; Raises Target Price to $422 From $236

THOMSON REUTERS
·
27 Feb

Madrigal price target raised to $405 from $400 at H.C. Wainwright

TIPRANKS
·
27 Feb

High Growth Tech Stocks In US For February 2025

Simply Wall St.
·
27 Feb

Madrigal Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $405 From $400

THOMSON REUTERS
·
27 Feb

U.S. RESEARCH ROUNDUP-Abbvie, Freeport-McMoran, Goldman Sachs

Reuters
·
27 Feb

Madrigal Pharmaceuticals Inc (MDGL) Q4 2024 Earnings Call Highlights: Strong Sales Growth and ...

GuruFocus.com
·
27 Feb

Madrigal’s Financial Vulnerability: Overreliance on Specialty Pharmacies Threatens Revenue Stability

TIPRANKS
·
27 Feb